Rocket Pharmaceuticals entered into a Loan and Security Agreement providing for up to five tranches of senior secured term loans totaling $150.0 million, with $35.0 million funded at closing on September 30, 2026. The facility bears interest at the greater of prime rate or 6.75% plus 2.40%, features a maturity date of October 1, 2030 (extendable to 2031), and includes an initial interest-only period through April 1, 2029. The company also issued warrants to purchase up to 1,755,853 shares of common stock at $2.99 per share to the lenders. Rocket Pharmaceuticals is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases.
